Sisätautien yksikkö
Department of Internal Medicine

Julkaisut 2008
Publications 2008

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.

1 Bakris G et al. Cardiovascular protection for all individuals at high risk: evidence-based best practice.
2 Balkau B et al. Physical activity and insulin sensitivity: the RISC Study.
3 Boesgaard TW et al. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients - the EUGENE2 study.
4 Bonnet F et al. Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects.
5 Califf RM et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
6 Chen W-M et al. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels.
7 Chibalin AV et al. Downregulation of diacylglycerol kinase delta contributes to hyperglycemia-induced insulin resistance.
8 De Mello V et al. Downregulation of genes involved in NFkappaB activation in peripheral blood mononuclear cells after weight loss is associated with the improvement of insulin sensitivity in individuals with the metabolic syndrome: the GENOBIN study.
9 de Mello VDF et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome.
10 Friedrich B et al. Variance of the SGK1 gene is associated with insulin secretion in different European populations: results from the TUEF, EUGENE2, AND METSIM studies.
11 Halinen M et al. Diagnoosien kirjaamiskäytännöissä kehittämisen varaa.
12 Halinen M et al. Laskimotukoksen ehkäisy lonkan ja polven elektiivisen tekonivelleikkauksen yhteydessä.
13 Hallikainen M et al. Effects of plant stanol esters on serum cholesterol concentrations, relative markers of cholesterol metabolism and endothelial function in type 1 diabetes.
14 Hammerstedt A et al. High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.
15 Heikkinen M, Saarela A. Onko endoskopiatoiminta Suomessa riittävän tasokasta?
16 Helisalmi S et al. Genetic study between SIRT1, PPARD, PGC-1alfa genes and Alzheimer's disease.
17 Hämäläinen S et al. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences.
18 Jantunen E. Myelooman muuttuva hoito.
19 Jantunen E. Aikuispotilaiden autologiset kantasolusiirrot.
20 Jantunen E et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry.
21 Jantunen E et al. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis.
22 Jantunen E, Kuittinen T. Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues.
23 Jantunen E et al. Iäkkäiden potilaiden pahanlaatuisten veritautien hoito.
24 Jantunen E et al. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients.
25 Jokinen JJ et al. Prospective assessment of quality of life of octogenarians after cardiac surgery: factors predicting long-term outcome.
26 Juutilainen A et al. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects.
27 Jääskeläinen J et al. Androgen receptor gene CAG repeat length in women with metabolic syndrome.
28 Kaipiainen-Seppänen O et al. Two pathogenic CIAS1 mutations and plasma cytokine profile in a Finnish patient with familial cold autoinflammatory syndrome responsive to anakinra.
29 Kallio P et al. Inflammation markers are modulated by responses to diets differing in postprandial insulin responses in individulas with the metabolic syndrome1-3.
30 Karavirta L et al. Estimation of maximal heart rate using the relationship between heart rate variability and exercise intensity in 40-67 years old men.
31 Karinen H. Genetics and Family Aspects of Coeliac Disease.
32 Kemppainen TA et al. Unkilned and large amounts of oats in the coeliac disease diet: a randomized, controlled study.
33 Ketonen M et al. Long-term prognosis after coronary artery bypass surgery.
34 Kilpeläinen TO et al. Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome. The Finnish Diabetes Prevention Study.
35 Kilpeläinen TO et al. SNPs in PPARG associte with type 2 diabetes and intract with physival activity.
36 Koikkalainen JR et al. Early familial dilated cardiomyopathy: Identification with determination of disease state parameter from cine MR image data.
37 Koivula M-K et al. Sensitivity and specificity of autoantibodies binding to citrullinated carboxyterminal telopeptides of types I and II collagens in an early arthritis series.
38 Kolehmainen M et al. Weight reduction modulates expression of genes involved in extracellular matrix and cell death: the GENOBIN study.
39 Koukkunen H et al. Coronary events in persons aged 75 years or older in Finland from 1995 to 2002. The FINAMI study.
40 Kozakova M et al. Body composition and common carotid artery remodeling in a healthy population.
41 Kröger H et al. Murtumat. Osteoporoosi. Kuntoutus.
42 Laakso M. Diabetes as a 'cardiovascular disease equivalent': implications for treatment.
43 Laakso M et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.
44 Laaksonen DE et al. Long-term repeatability of measures of early insulin secretion derived from an intravenous glucose tolerance test and conversion from impaired glucose tolerance to diabetes.
45 Laaksonen DE et al. Dyslipidaemia as a predictor of hypertension in middle-aged men.
46 Laitinen T et al. Electrocardiographic alterations during hyperinsulinemic hypoglycemia in healthy subjects.
47 Lappalainen T et al. Serum concentrations and expressions of serum amyloid A and leptin in adipose tissue re interrelated: the Genobin study.
48 Lee JC et al. WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels.
49 Lehto SM et al. Metabolic syndrome - the impact of depression .
50 Lehto SM et al. Low HDL cholesterol associates with major depression in a sample with a 7-year history depressive symptoms.
51 Leppä S et al. Diffuusin suurisoluisen B-solulymfooman hoito.
52 Lindi V et al. The G-250A polymorphism in the hepatic lipase gene promotor is associated with changes in hepatic lipase activity and LDL cholesterol:The KANWU study.
53 Liu X-Q et al. IL5RA and TNFRSF6B gene variants are associated with sporadic IgA nephropathy.
54 Magga J et al. Significance of plasma levels of N-Terminal pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
55 Miettinen KH et al. Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy.
56 Miettinen KH et al. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure.
57 Miettola J et al. Metabolic syndrome is accociated with self-perceived depression.
58 Miettola J et al. Metabolic syndrome is associated with impaired health-related quality of life: Lapinlahti 2005 study.
59 Mäkinen H. Disease Activity and Remission in Rheumatoid Arthritis. Comparison of Available Disease Activity Measures and Development of a Novel Disease Activity Index. The Mean Overall Index for Rheumatoid Arthritis (MOI-RA).
60 Mäkinen V-P et al. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes.
61 Mäntyselkä P et al. Chronic pain, impaired glucose tolerance and diabetes: A commynity-based study.
62 Mäntyselkä P et al. Glucose regulation and chronic pain at multiple sites.
63 Niinisalo P et al. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the health 2000 study.
64 Nyman H et al. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.
65 Ojala K et al. Characterization of metabolic syndrome among forensic psychiatric inpatients.
66 Ojala K et al. Statins are effective in treating dyslipidemia among psychiatric patiens using second-generation antipsychotic agents.
67 Patel S et al. Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects.
68 Peura P et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
69 Purokivi M et al. Utility of cough response during hypertonic histamine challenge in diagnosing asthma.
70 Ruotsalainen E et al. Markes of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects.
71 Saharinen T et al. Health-related quality of life in a population-based sample of men with long-term mental symptoms.
72 Saltevo J. Low-Grade Inflammation and Adiponectin in the Metabolic Syndrome.
73 Saltevo J et al. Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with insulin sensitivity: a population-based study.
74 Saltevo J et al. Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population-based study.
75 Samani NJ et al. Coronary artery disease - associated locus on chromosome 9p21 and early markers of atherosclerosis.
76 Saraheimo M et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.
77 Savolainen E et al. Serum soluble CD30 in early arthritis: a sign of inflammation but not a predictor of outcome.
78 Shaw JE et al. Sleep-disordered breathing and type 2 diabetes. A report from the International Diabetes Federation Taskforce on Epidemiology and Prevention.
79 Sillanpää E et al. Body composition and fitness during strength and/or endurance training in older men.
80 Sipilä K et al. Metabolic syndrome and carotid intima media thickness in the Health 2000 Survey.
81 Staiger H et al. A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study.
82 Stancáková A et al. Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance.
83 Talasniemi JP et al. Analytical investigation: assay of D-lactate in diabetic plasma and urine.
84 The DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose. Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
85 The ORIGIN Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
86 Timonen P et al. Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy.
87 Tolonen N et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes.
88 Ungaro P et al. Molecular cloning and characterization of the human PED/PEA-15 gene promoter reveal antagonistic regulation by hepatocyte nuclear factor 4alpha and chicken ovalbumin upstream promoter transcription factor II.
89 Usvasalo A et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
90 Valtonen M et al. Hopelessness - novel facet of the metabolic syndrome in men.
91 van Gaal FC et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
92 Wadén J et al. Physical activity and diabetes complications in patients with type 1 diabetes. The Finnish Diabetic Nephropathy (FinnDiane) Study.
93 Wang J et al. The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly people in Finland.
94 Zeggini E et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.

Sisätautien yksikkö Department of Internal Medicine
Julkaisutietokanta 27.8.2009 Publications Data Base 27.8.2009